Free Trial
NASDAQ:ONMD

OneMedNet 4/15/2025 Earnings Report

OneMedNet logo
$0.59 +0.04 (+6.31%)
Closing price 04:00 PM Eastern
Extended Trading
$0.58 -0.01 (-2.03%)
As of 07:24 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

OneMedNet EPS Results

Actual EPS
-$0.05
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

OneMedNet Revenue Results

Actual Revenue
$0.03 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

OneMedNet Announcement Details

Quarter
Time
After Market Closes
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

OneMedNet Earnings Headlines

Elon’s BIGGEST warning yet?
Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… The "experts" said Elon was finished and Tesla was headed for bankruptcy. Now they're saying the same thing, but Jeff has uncovered Tesla's next breakthrough.
See More OneMedNet Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like OneMedNet? Sign up for Earnings360's daily newsletter to receive timely earnings updates on OneMedNet and other key companies, straight to your email.

About OneMedNet

OneMedNet (NASDAQ:ONMD) (NASDAQ:ONMD) is a leading provider of cloud-based eClinical solutions designed to streamline and enhance the management of clinical trials. Since its founding in 2004, the company has focused on delivering integrated software tools that cover every stage of study execution, from protocol design to patient close‐out. OneMedNet’s platform combines electronic data capture (EDC), randomization and trial supply management (RTSM), and clinical trial management system (CTMS) capabilities in a single, scalable environment tailored for biopharmaceutical sponsors, contract research organizations (CROs) and academic research institutions.

The company’s flagship offering includes a flexible EDC module that supports customizable case report forms, real‐time data validation and audit trails to ensure regulatory compliance. Its RTSM functionality automates patient randomization and investigational product distribution, while the CTMS component provides study oversight through milestone tracking, site payments and resource planning. In addition to these core modules, OneMedNet offers eConsent solutions, electronic patient‐reported outcomes (ePRO) tools and a range of analytics and reporting features that enable sponsors to make data‐driven decisions and accelerate time to market.

OneMedNet serves a diverse client base across North America, Europe and Asia-Pacific, with a particular focus on oncology, rare disease and central nervous system studies. The platform is designed to support Phase I through IV trials across multiple therapeutic areas, accommodating both large global programs and smaller investigator‐initiated studies. By leveraging a hosted, software‐as‐a‐service model, the company offers rapid study setup, low upfront costs and continuous product enhancements delivered via quarterly releases.

The company’s executive team is led by CEO David J. Marshall, a veteran of the life sciences technology sector, and CFO Maria L. Rodriguez, who brings more than a decade of experience in healthcare finance. Under their leadership, OneMedNet has invested heavily in research and development to incorporate advances in artificial intelligence, risk‐based monitoring and decentralized trial functionality. The organization maintains strategic partnerships with leading research centers and industry consortia, further solidifying its reputation as an innovative collaborator in the clinical research ecosystem.

View OneMedNet Profile

More Earnings Resources from MarketBeat